We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Having met the MHRA’s rigorous standards of safety, quality and effectiveness, the semaglutide tablet has been approved in the UK for weight loss and weight management.
Topical hormone products such as gels and creams can be absorbed accidentally by pets through close contact.
New AI sandbox will help make medicines safer, speed up development, and reduce reliance on animal testing.
As with all medicines, the MHRA will keep the safety and effectiveness of Nipolcalimab under close review.
Avacopan is used in the treatment of some rare autoimmune diseases affecting small blood vessels.
The adjuvanted trivalent influenza vaccine works by stimulating the immune system to produce its own protection against flu.
Resmetirom is used in adults who have experienced inflammation and cell damage, resulting in scarring.
The raid on a Northamptonshire estate dismantled what is believed to be a major illicit manufacturing and distribution operation
As with any medicine, the MHRA will keep the safety and effectiveness of rilzabrutinib under close review.
Jason is an experienced technology leader with over 25 years working in tech leadership and health informatics.
Essential advice on protecting your medicines during extreme heat and staying safe.
The MHRA launches public consultation on new framework that could lead to earlier licensing for therapies for up to 3.5 million people in the UK.
Proposed Rare Disease Therapies Framework introduces Investigational Marketing Authorisation and compressed development pathways – industry urged to respond
MHRA announces new programme of events and greater engagement with industries, researchers, local NHS and government in Wales.
Innovation doesn’t wait for the rules to catch up. The question is whether we can build a system agile and flexible enough to keep pace.
As with any medicine, the MHRA will keep the safety and effectiveness of Vyjuvek under close review.
The MHRA hub in Belfast will strengthen collaboration and engagement with local industry, academia and the healthcare sector.
Updated safety advice has been issued to strengthen warnings about potential psychiatric and sexual dysfunction linked to finasteride and to provide precautionary advice on dutasteride.
To future-proof the sector and ensure regulation keeps up with scientific and technological developments, the MHRA is consulting on proposed changes to how gene therapies are defined in UK legislation.
New pre-market regulatory requirements for medical devices and in vitro diagnostic devices entering the GB market have been published.
Do not include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).